Abl激酶抑制剂治疗新型冠状病毒肺炎的研究进展

Abl kinase inhibitors in the treatment of COVID-19

目前,新型冠状病毒肺炎疫情已经构成全球大流行,严重影响世界公共卫生安全,但仍无有效抗病毒药物。Abl激酶参与体内一系列病理生理变化,在病毒感染中发挥重要作用。Abl激酶抑制剂能够在体外抑制冠状病毒,并具有广泛抗病毒活性和促进肺损伤后肺泡上皮修复等功能。本文介绍Abl激酶抑制剂治疗新型冠状病毒肺炎的相关研究进展。

At present,COVID-19 has been characterized as a pandemic,seriously affecting the public health security of the world.No specific antivirals are available to severe acute respiratory syndrome coronavirus 2.The Abl kinase participates in a series of physiopathological changes in body and plays an important role in viral infections.Abl kinase inhibitors are potent antagonists of coronaviruses and many other viruses in vitro and promote alveolar epithelial accelerated recovery following lung injury.This article reviews the research progress of Abl kinase inhibitors in the treatment of COVID-19.